Cannara Biotech Inc. (LOVE) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Cannara Biotech, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.058 Good morning, everyone. Welcome to Canara Biotech's Q2 2026 00:00:05.058 -- 00:00:08.724 earnings call for the three months ended February 28th, 2026. 00:00:08.724 -- 00:00:10.186 Today's 00:00:10.186 -- 00:00:15.514 presenter is Nicholas Sosiak, CFO, joined by Zohar Kriberat, founder 00:00:15.514 -- 00:00:19.960 and CEO. At this time, all participants are in a listen-only mode. 00:00:19.960 -- 00:00:23.566 After the speaker's presentation, there will be a question and answer session. 00:00:23.566 -- 00:00:28.735 To ask a question during the session, you will need to press star 11 on your telephones. 00:00:28.735 -- 00:00:32.400 You will then hear an automated message advising that your hand is raised. 00:00:32.400 -- 00:00:35.504 To withdraw your question, please press star 11 again. 00:00:35.504 -- 00:00:38.788 Please be advised that today's conference is being recorded. 00:00:38.788 -- 00:00:44.255 Before we begin, please refer to slide two and three for our caution regarding forward-looking 00:00:44.255 -- 00:00:49.802 statements and non-GAAP measures. I will now turn the call over to Nicholas. 00:00:49.802 -- 00:00:52.063 You may begin. 00:00:54.268 -- 00:00:57.895 Good morning, everyone, and thank you for joining our Q2 earnings call. 00:00:57.895 -- 00:01:03.040 Q2 reflects continued execution of a model that is delivering consistent and profitable 00:01:03.040 -- 00:01:08.066 growth. For the quarter, Canara delivered 27.2 million in revenue with 00:01:08.066 -- 00:01:13.611 strong margins and profitability, generating 6 million of adjusted EBITDA and 2.9 00:01:13.611 -- 00:01:18.797 million of operating cash flow. This represents our 20th consecutive quarter 00:01:18.797 -- 00:01:24.002 of positive adjusted EBITDA and our 1...